Some small clinical reports support this combination, but dedicated large RCTs are still lacking
Those with existing cardiovascular conditions should be especially cautious and consult a provider before beginning treatment
Upon withdrawal, Semaglutide and Tirzepatide groups regained ~5% and ~20% of body weight
J.ZuderD
C0_ISCas: 350818-62-1), acetyl-L-carnitine-d3 HCl (Cas: 1334532-17-0), propionyl-L-carnitine-d3 HCl (Cas: 1334532-19-2), butyryl-L-carnitine-d3 HCl (Cas: 1334532-21-6), isovaleryl-L-carnitine-d9 HCl (Cas: 1334532-23-8), hexanoyl-L-carnitine-d3 HCl (Cas: 2483831-95-2), octanoyl-L-carnitine-d3 HCl (Cas: 1334532-24-9), decanoyl-L-carnitine-d3 HCl (Cas: 2483831-87-2), dodecanoyl-L-carnitine-d3 HCl (Cas: 2687960-76-3), myristoyl-L-carnitine-d9 HCl (Cas: 1334532-25-0), palmitoyl-L-carnitine-d3 HCl (Cas: 1334532-26-1), and octadecanoyl-L-carnitine-d3 HCl (Cas: 2245711-27-5)
In the expert opinion section, the author suggests that once-daily oral semaglutide might not replace the once-weekly subcutaneous semaglutide in treating type 2 diabetes
